Rosetta Genomics pointed out that colon cancer serum project is still in the early stage of development, and the company cannot provide any assurance that it will be successful in developing this product in its intended timeframe, or at all. Also the company cannot assure that the final product will effectively differentiate colon cancer from other types of cancers. However, the company has a commercial product called miRview that can identify around 25 types of cancer and help them work on the colon cancer alone. Rosetta Genomics also updated that they have identified the microRNA potential biomarkers on serum samples obtained from colon cancer patients in comparison to samples derived from control individuals.http://www.favstocks.com/rosetta-genomic...
The company is still gathering more data for further validation and are constantly reviewing the behavior of microRNA in health individuals and comparing it with patients who are suffering from colon cancer.